Stage 1 mesothelioma is localized. The cancer is confined to one side of the chest lining or one area of the abdomen and has ...

"The prognosis was so poor that the hospital called in grief counselors to speak with my family and help prepare them." ...

The risk of ovarian cancer increases steeply from around 45-years-old and is greatest in those aged between 75 and ...

In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA ...

Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to ...

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

The FDA has approved the first anti-PD-L1-based therapies for treatment of certain PD-L1-positive ovarian cancers. Pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph ...

Becki Ward had never felt comfortable with her weight so, like 1.6 million other adults in the UK, she began taking Mounjaro in October 2024. ‘At first it was working well, and supressing my appetite, ...

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.  | As Merck ...

MSD has received the US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) and Keytruda Qlex ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...